<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783042</url>
  </required_header>
  <id_info>
    <org_study_id>D1840M00006</org_study_id>
    <nct_id>NCT00783042</nct_id>
  </id_info>
  <brief_title>Exploratory Study of Coronary Flow Reserve Measurements, a Non-Invasive Method for Coronary Function Measurements</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Transthoracic Doppler Echocardiography Method as a Non-Invasive Method for Coronary Function Measurements; Ability to Detect Short-Term Statin Effects in Patients With Increased Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether the non-invasive ultrasound method for
      assessment of coronary blood flow, transthoracic Doppler echocardiography-coronary flow
      reserve (TTDE-CFR), can be used to measure drug effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CFR peak velocity within rosuvastatin group after 1 month of treatment compared to baseline</measure>
    <time_frame>Baseline and after 1 month of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of treatment effects on CFR peak velocities between groups after 1 month of treatment</measure>
    <time_frame>Baseline and after 1 month of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in CFR peak velocity within the rosuvastatin group after 3 months compared to baseline and to 1 month</measure>
    <time_frame>Bseline, after 1 month and after 3 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in other CFR parameters after one month rosuvastatin or placebo treatment; comparisons within groups and between groups</measure>
    <time_frame>Baseline and after 1 month of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma lipids, lipoproteins and other cardiovascular biomarkers after 1 month of treatment with rosuvastatin or placebo; comparisons within groups and between groups</measure>
    <time_frame>Baseline and after 1 month of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Inflammatory Activity in Coronary Arteries</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet, oral, once daily for 1 month (double blind)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males aged 45-75 years or females aged 60-75 years inclusive

          -  Carotid and/or femoral atherosclerotic plaque, as assessed by carotid ultrasound
             examination within the last 5 years

          -  Abnormal concentrations of lipids or lipoproteins in the blood

          -  Provision of signed informed consent

        Exclusion Criteria:

          -  Treatment with statins or other lipid-lowering drugs, e.g. fibrates, nicotinic acid,
             cholesterol absorption inhibitor, within the last 6 months before randomisation

          -  Current smoking or snuff tobacco use

          -  Major CV event (myocardial infarction (MI), stroke/ transitory ischemic attack (TIA),
             Acute Coronary Syndrome (ACS), revascularisation) within the last 6 months before
             randomisation

          -  Symptomatic carotid stenosis, atrioventricular (AV) block, QT-prolongation, atrial
             fibrillation, sinus node disease (such as sick sinus syndrome or symptomatic
             bradycardia), chronic obstructive pulmonary disease (COPD) or asthma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Björn Fagerberg, MD, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wallenberg LaboratorySahlgrenska University Hospital, S-413 45 Göteborg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Leonsson-Zachrissson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D Mölndal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>June 29, 2009</last_update_submitted>
  <last_update_submitted_qc>June 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Björn Carlsson MD, PhD, Medical Science Director, Clinical Discovery Team CV/GI</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>TTDE-CFR</keyword>
  <keyword>coronary artery function</keyword>
  <keyword>cardiovascular biomarkers</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>Crestor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

